Clinical Trial Update: Repeatability of Magnetic Resonance Imaging in Patients With IDH1 Mutant Glioma on Ivosidenib [NA]

View source ↗

Summary

This clinical trial update indicates that the study evaluating MRI repeatability in IDH1-mutant glioma patients treated with Ivosidenib has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Low-grade Glioma

Drugs mentioned

• Ivosidenib (ivosidenib)

Snippet

Sponsor: Duke University | Conditions: Low Grade Glioma of Brain | NA | Status: WITHDRAWN